321 results about "Quinolizidines" patented technology

The invention discloses a new gene purE1 which has high degradability on quinoline. Experiment shows that by using the purE1 gene to transform a microbe, the microbe can obtain degradation activity on quinoline, and the maximal degradation concentration of the degradation activity of the microbe provided by the purE1 gene and its coded protein is up to 850 mg/L. The invention has very important practical application value for the treatment of quinoline contaminants.

Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.

The invention discloses a quinoline compound, and a preparation method, an intermediate, a medicinal composition and an application thereof/ The invention provides a quinoline compound represented by formula 1 shown in the specification, and its pharmaceutically acceptable salts, solvates, metabolites, metabolism precursors or medicinal precursors. The quinoline compound has a good inhibition effect on tyrosine kinases C-Met, and can be used for preparing medicines for prevention, treatment or adjuvant treatment of many C-Met expression or activity related diseases, especially tumor diseases.

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.

The invention relates to new substituted quinoline derivatives presented in general formula (1a), or general formula (1b) or general formula (1c), a medical acid added salt, a stereochemical heterogeneous formula and a tautomeric form thereof. The compound can be used for curing mycobacterium diseases, in particular to diseases caused by pathogenic mycobacteria, such as mycobacterium tuberculosis, mycobacterium bovis, mycobacterium avium and mycobacterium marinum and is particularly defined as following: R1 is mutually independent bromines; p is equal to 1, R2 is an alkoxy, and R3 is a randomly substituted phenyl or naphthyl; q is equal to 1, R4 and R5 are mutually independent hydrogen and a methyl or an ethyl, and R6 is hydrogen; r is equal to 0 or 1 and R7 is hydrogen. The invention also relates to a composition of the compound, applications of the compound of the composition to medicines for curing the mycobacterium diseases, and a method for preparing the compound of the composition, which comprises a medical carrier and is used as activated ingredient of curable effective quantity.

The invention discloses a non-hydrodenitrogeneration method for catalytically cracked gasoline. The non-hydrodenitrogeneration method for the catalytically cracked gasoline comprises the following steps: first, mixing a liquid denitrifying agent with the catalytically cracked gasoline by using a static mixer, standing, depositing, and pre-removing alkali nitrides; and then, performing contact reaction with a solid denitrifying agent through a fixed bed for finely removing the alkali nitrides. Through matching of the liquid denitrifying agent and the solid denitrifying agent, the alkali nitrides such as aliphatic amines, pyridines, quinolines and anilines and the like can be removed by pre-removing and finely removing steps; after the treatment of the liquid denitrifying agent, 80-90 percent of the alkali nitrides can be removed, and after the catalytically cracked gasoline passes through the solid denitrifying agent filled in a form of the fixed bed, the alkali nitrides can be removedcompletely, so that the negative effect of the alkali nitrides on a subsequent hydrodesulfurization catalyst can be completely eliminated. Therefore, the deep hydrodesulfurization of the catalytically cracked gasoline can be realized.

The invention relates to quinoline compound, a synthesis method and the application for preparing medicines of camptothecin alkaloid. The syntheticroute is concise, high-efficient and economical, and can play a great role in promoting the later industrialized production of camptothecin alkaloid.

The invention discloses novel organic berberine glycyrrhetinic acid enantiomeric salts used for medicines and a production method and application thereof. The chemical name of the organic berberine glycyrrhetinic acid enantiomeric salts is: 5,6-dihydrogen-9,10-dimethoxybenzo[g]-1,3-benzodioxolane[5,6-a]quinolizidine.18a(beta),3beta-hydroxyl-11-oxooleanane-12-olefine-30-formate. The production method comprises the following steps of: respectively dissolving berberine and a glycyrrhetinic acid enantiomer in 80 percent ethanol according to a medicament eutecticum principle, mixing the two liquids, stirring for 2 hours, removing the ethanol under reduced pressure, and treating by using ethyl acetate to prepare the berberine glycyrrhetinic acid enantiomeric salts. The organic salts with dual parent nuclei have positive practical significance for resisting diseases such as tumors, diabetes, chronic inflammatory diseases such as rheumatoid arthritis, hepatitis, Alzheimer disease and the like of human and developing medicines.

The invention discloses a red to near-infrared phosphorescent iridium complex light-emitting material and application thereof to an electroluminescent device, belongs to the technical field of organic electroluminescence, and particularly relates to a dark red to near-infrared phosphorescent iridium complex light-emitting material with a 1-phenyl quinoline derivative as a first ligand and an amidino-guanidyl derivative as an auxiliary ligand. The general formula of a compound of the material is shown as follows. The red to near-infrared phosphorescent iridium complex light-emitting material is doped in a main material as a phosphorescent object to form a light-emitting layer of the organic electroluminescent device. The compound has the advantages that the preparation process is simple, and the manufactured electroluminescent device is high in efficiency and long in service life. The device can be used in the application fields of panel display, illumination, light sources and the like. The formula is shown in the description.

A 4-substituted phenylmino-3-nitroquinoline compound has the suppression action to the reproduction of tumor cells rich in epidermal growth factor receptor. Its preparing process and usage are also disclosed.

The invention discloses a matrine derivative which comprises quinoline, benzene rings, benzdioxan, naphthalene nucleus and indole codonopsine derivatives. The invention further discloses application of the derivative to a preparation method and pharmacy.

The invention provides a tetrahydroquinoline alkaloid Malaysiensin with immunosuppression activity and a production method and application of the tetrahydroquinoline alkaloid Malaysiensin with the immunosuppression activity. The compound is obtained by conducting SFM solid medium fermentation on Streptomyces sp.DSM 4137 and separating and purifying a fermentation product. The compound can significantly inhibit ConA-induced proliferation of T cells, an immunosuppression effect of the compound is equivalent to that of an immunosuppressor cyclosporin A which is clinically and widely used, and action mechanism studies show that Malaysiensin exerts the immunosuppression activity for a targeted NFAT signal path, is an efficient immunosuppressor, and can be used for producing immunosuppressive medicines for organ transplantation and autoimmune diseases.

The invention relates to a pyridine-quinoline compound, a preparation method thereof and an organic light-emitting device made from the compound. The pyridine-quinoline derivative is obtained by connection with boronic acid derivatives with different substituting groups on the basis of difluoropyridine-[2,3-g]quinoline; the preparation process is simple, the reaction condition is mild, the pyridine-quinoline derivative can be taken as an electron transport material to be applied to organic light-emitting devices. According to the pyridine-quinoline derivative, the preparation method and the organic light-emitting device, the prepared pyridine-quinoline compound is high in efficiency, high in brightness, long in service life, better in charge transfer capacity and high in glass transition temperature and non-crystallizable when applied to organic light-emitting devices.

The invention discloses 2,8-bis(trifluoromethyl)quinoline 4-modified derivatives, a preparation method thereof and an application of the derivatives in prevention and treatment of plant diseases. Thetest results show that the compounds have excellent control effect on sclerotiniasclerotiorum, rhizoctonia solani, wheat phytoalexin, pyriculariaoryzae, phyllostictazeae, botrytis cinerea, watermelongummy stem blight and cotton fusarium wilt. The derivatives of the invention are simple in preparation process, low in price and easy to obtain raw materials, high in product purity and wide in bactericidal spectrum, and are expected to be developed into a new bactericide.

The invention relates to a novel preparation method of 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a] quinolizidine-2-ketone. The technological method is economic, simple, convenient and high in total yield, and is suitable for industrial production.

The invention relates to a 6,7-disubstituted-4-aromatic quinoline derivative shown as a general formula I as well as pharmaceutically-acceptable salt, a hydrate, a solvate and pro-drug thereof, wherein substituents R1, X and Y have meanings given in the description. The invention further relates to a compound with a strong effect on inhibiting c-Met kinase shown as the general formula I and further relates to application of the compound and pharmaceutically-acceptable salt, a hydrate, a solvate and pro-drug thereof to preparation of a drug for treating a disease caused by the abnormally-high expression of the c-Met kinase, in particular to application to preparation of a drug for treating and/or preventing a cancer.

The invention discloses a synthesis method of 11H-indolo [3,2-c] quinoline compounds, belonging to the technical field of synthesis of indolo quinoline compounds. The technical scheme of the invention is mainly characterized by taking 2-(2-bromo-aryl)-1H-indolo, ammonia water and aldehyde compounds as raw materials, taking dimethyl sulfoxide or N,N-dimethyl formamide as a solvent, taking transition metal salt as a catalyst, taking potassium carbonate as alkali, and taking L-proline as a ligand to carry out one-pot, two-step and three-component tandem reaction to synthesize 11H-indolo [3,2-c] quinoline compounds with multiple substitute modes. The synthesis method disclosed by the invention has the advantages that starting materials are simple and easy to prepare, and substrates are wide in range of application, high in regioselectivity and simple in operation.

The present invention relates to a quinoline compound, as well as a preparation method and medical use therefor. Specifically, the present invention relates to a novel quinolone compound represented by the general formula (I) and a method for preparing the same, as well as a use therefor as an inhibitor for a plurality of protein kinases, and a use in the prevention and/or treatment of cancer in particular; the definition of each group in the general formula (I) is the same as the definition in the description.

The invention discloses a method for preparing an N-(5-chloro-8-quinolyl)benzamide compound by adopting an electrochemical micro-channel reaction device, which comprises the following steps: dissolving an 8-(benzoylamino)quinoline compound in a first organic solvent to prepare a reaction solution A; dissolving dichloromethane and copper acetate in a second organic solvent, and preparing a reactionsolution B; respectively pumping the reaction solution A and the reaction solution B into a micro mixer of an electrochemical micro-channel reaction device at the same time for mixing, and then enabling the mixture to flow into a micro-reactor for reaction, thereby obtaining the product. Compared with the prior art, the method has the advantages that a traditional oxidizing agent is not needed, and a new method for electrocatalytically and selectively preparing the chloroquinoline compound by taking dichloromethane as a chlorination reagent through a micro-flow field is creatively developed;meanwhile, a micro-channel reaction device is utilized, so that the reaction time is greatly shortened, the reaction conversion rate is increased, and the yield is remarkably increased and reaches 85%.

The invention relates to the field of medicinal chemistry and in particular relates to 4-imidazolyl quinoline and quinazoline ketone aromatizing enzyme inhibitors. The invention further discloses a preparation method and pharmacological activity of the inhibitors, a medicinal composition containing the compounds as well as the medical application of the inhibitors, in particular the medical application of the inhibitors in preventing or treating estrogen maintaining diseases such as breast cancers, endometrial cancers, female sexual precocity, gynecomastia and the like.

The invention discloses a monatom and particle synergistic supported metal catalyst as well as a preparation method and application thereof. According to the metal catalyst disclosed by the invention, metal is uniformly loaded on a carrier in a form of coexistence of single atoms and nano-particles. The metal is at least one of Ir, Ru, Rh, Pd, Co and Pt. The pore diameter of the carrier is 0.5-10nm, and the specific surface area is 200-1500m<2>/g. The carrier is any one of mesoporous carbon, a mesoporous molecular sieve and activated carbon. The monatom and particle synergistic supported metal catalyst shows very excellent activity and selectivity in hydrogenation reaction of quinoline, aromatic nitryl, aromatic aldehyde or carbonyl compounds, and the catalytic activity of the monatomic and particle synergistic supported metal catalyst is higher than that of currently reported catalysts under the same or similar reaction conditions; and the catalyst shows a very excellent industrial application prospect. The monatom and particle synergistic supported metal catalyst is prepared by using a simple dipping and high-temperature pyrolysis method, the method is simple, the metal loading capacity is adjustable, and the catalyst has good reproducibility and is suitable for various metals.